Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 75 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $181.84, for a total transaction of $13,638.00. Following the completion of the sale, the executive vice president directly owned 21,308 shares in the company, valued at $3,874,646.72. This represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Michael Feld also recently made the following trade(s):

• On Monday, January 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $202.73, for a total value of $15,204.75.
• On Friday, December 26th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $196.08, for a total value of $14,509.92.
• On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $193.36, for a total transaction of $14,502.00.

Becton, Dickinson and Company Trading Down 0.4%

BDX stock traded down $0.62 during trading on Friday, hitting $176.04. 4,298,153 shares of the company traded hands, compared to its average volume of 3,165,117. The firm has a market capitalization of $50.12 billion, a PE ratio of 28.72, a P/E/G ratio of 12.81 and a beta of 0.25. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The company has a 50-day moving average of $195.68 and a 200-day moving average of $192.08. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter in the previous year, the company earned $3.43 earnings per share. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BDX. Wellington Management Group LLP lifted its holdings in shares of Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares during the period. Vanguard Group Inc. raised its position in Becton, Dickinson and Company by 15.4% in the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after acquiring an additional 4,305,947 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in Becton, Dickinson and Company by 23,219.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after purchasing an additional 4,137,888 shares in the last quarter. Norges Bank purchased a new stake in Becton, Dickinson and Company in the second quarter worth about $653,377,000. Finally, First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after buying an additional 3,268,478 shares during the period. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of several research reports. TD Cowen lifted their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Zacks Research cut Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, Citigroup dropped their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $195.46.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.